Etoposide pharmacokinetics in a jaundiced infant with letterer-siwe variant of langerhans cell histiocytosis.
An infant with hepatocellular jaundice due to Langerhans cell histiocytosis was treated and responded well to intravenous etoposide. Pharmacokinetics demonstrated similar clearance and AUC data in both the jaundiced and non-jaundiced states but myelosuppression was greater when the infant was jaundiced. Children with hepatocellular jaundice require dose reductions of etoposide, despite the similar drag pharmacokinetics to the non-jaundiced state. The mechanisms involved are discussed.